Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPoitiers University Hospital

About this trial

In intensive care units (ICUs), around 20% of patients experience respiratory failure after planned extubation. Nearly 40-50% of them eventually require reintubation with subsequently high mortality rates reaching 30-40%. NIV used as rescue therapy to treat post-extubation respiratory failure could increase the risk of death. However, NIV may avoid reintubation in a number of cases, and recent large-scale clinical trials on extubation have shown that around 40 to 50% of patients with post-extubation respiratory failure are actually treated with NIV. Whereas high-flow nasal oxygen has never been specifically studied for management of post-extubation respiratory failure, this respiratory support could also in this setting constitute an alternative to standard oxygen or NIV. Given the best noninvasive respiratory support strategy in patients with post-extubation respiratory failure remains unknown, we have decided to assess whether NIV alternating with high-flow nasal oxygen as compared to high-flow nasal oxygen alone may decrease mortality of patients in ICUs with post-extubation respiratory failure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Duration of invasive mechanical ventilation of more than 24h in the ICU before extubation.

Clinical criterion persisting for at least 30 minutes: a respiratory rate exceeding 25 breaths per minute or clinical signs of respiratory distress with increased accessory muscle activity.

Blood gas criterion: Hypoxemia defined as PaO2/FiO2 ratio below 150 mm Hg or respiratory acidosis defined as pH below 7.35 units and PaCO2 above 45 mm Hg. For patients under standard oxygen, FiO2 will calculated according to the following formula: FiO2 = 0.21 + 0.03 x (oxygen flow L/min).

Informed consent from the relatives or the patient himself, or emergency inclusion procedure in case of inability of patient or proxy to give consent.

Disqualifiers

NIV at home

ICU admission for peripheral neuromuscular disease type Guillain-Barré syndrome or myasthenia gravis.

Upper airway obstruction as main reason for post-extubation respiratory failure

Urgent need for reintubation (respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, or severe hypoxemia defined as SpO2 lower than 90% despite maximal oxygen support)

Trial design

Design model

Parallel

Treatments tested in this trial

  • High-Flow Oxygen

    Procedure/Surgery

    Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula

  • Non invasive ventilation

    Procedure/Surgery

    NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation

Treatment groups

670 Participants
are divided into 2 treatment groups
Group A: High-Flow OxygenActive comparator 1 intervention
Group B: NIV alternating with High-Flow OxygenExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Mortality at 28 days after post-extubation respiratory failure

Death between post-extubation respiratory failure and 28 days after post-extubation respiratory failure

Time frame
Day 28

Secondary outcomes

1

Time to death between randomization and day 28

Death between randomization and day 28

Time frame
Day 28
2

Reintubation within the 48 hours, 7 days and 28 days following post-extubation respiratory failure

Reintubation rates within the 48 hours, 7 days and 28 days following respiratory failure

Time frame
Hour 48 Day 7 and Day 28
3

Ventilator-free days at day 28,

number of days alive and without invasive mechanical ventilation between randomization (day 1) and day 28.

Time frame
Day 28
4

Length of stay in ICU and length of stay in hospital.

Length of stay in ICU and length of stay in hospital in days

Time frame
Day 90

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.